| Title | Influence of sucralfate on trilisate bioavailability. | | Author(s) | Schneider DK, Gannon RH, Sweeney KR, DeFusco PA | | Institution | Department of Pharmacy, Hartford Hospital, CT 06115. | | Source | J Clin Pharmacol 1991 Apr; 31(4):377-9. | | MeSH | Administration, Oral
Adult
Anti-Inflammatory Agents, Non-Steroidal
Biological Availability
Choline
Female
Humans
Male
Salicylates
Sucralfate
| | Abstract | Twelve healthy human volunteers were randomized to receive either choline-magnesium trisalicylate (CMT) 1.5 g orally every 12 hours or a combination of CMT plus sucralfate 1 g orally every 6 hours for 5 days before the blood sampling day. After a 3-week washout period, the subjects were crossed over to receive the alternate treatment for 5 days. The mean (+/- SD) area under the curve was 2668 (729) mg - hr/L and 2748 (716) mg - hr/L for CMT and CMT/sucralfate treatments, respectively. Mean (+/- SD) maximum concentration was 275 (69) mg/L and 283 (75) mg/L for CMT and CMT/sucralfate administrations, respectively. Mean (+/- SD) time to maximum concentration for CMT and CMT/sucralfate treatments was 1.8 (0.6) hours and 1.7 (0.7) hours, respectively. There were no significant differences detected for any parameter, therefore sucralfate does not affect rate or extent of CMT absorption. | | Language | eng | | Pub Type(s) | Clinical Trial
Journal Article
Randomized Controlled Trial
| | PubMed ID | 2037712 |
|
